Associations between plasma lysophospholipids concentrations, chronic kidney disease and the type of renal replacement therapy
Abstract Background Lysophosphatidic acid (LPA) and lysophosphatidylcholine (LPC) are bioactive lysophospholipids involved in the pathogenesis of renal diseases, especially the renal fibrosis. Plasma LPC concentrations in chronic kidney disease (CKD) patients are lower or similar to those observed i...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-04-01
|
Series: | Lipids in Health and Disease |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12944-019-1040-5 |
id |
doaj-5f734c0ee06a47be848f85fd236b1c69 |
---|---|
record_format |
Article |
spelling |
doaj-5f734c0ee06a47be848f85fd236b1c692020-11-25T01:31:37ZengBMCLipids in Health and Disease1476-511X2019-04-011811910.1186/s12944-019-1040-5Associations between plasma lysophospholipids concentrations, chronic kidney disease and the type of renal replacement therapyAnna Michalczyk0Barbara Dołęgowska1Rafał Heryć2Dariusz Chlubek3Krzysztof Safranow4Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in SzczecinDepartment of Microbiology, Immunology and Laboratory Medicine, Pomeranian Medical University in SzczecinDepartment of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University in SzczecinDepartment of Biochemistry and Medical Chemistry, Pomeranian Medical University in SzczecinDepartment of Biochemistry and Medical Chemistry, Pomeranian Medical University in SzczecinAbstract Background Lysophosphatidic acid (LPA) and lysophosphatidylcholine (LPC) are bioactive lysophospholipids involved in the pathogenesis of renal diseases, especially the renal fibrosis. Plasma LPC concentrations in chronic kidney disease (CKD) patients are lower or similar to those observed in control groups, but less is known about the LPA concentrations. The main aim of the study was the analysis of associations of chronic kidney disease and renal replacement therapy with the plasma LPA concentrations. We have also analyzed the relationship between the plasma concentrations of LPA and LPC. Material and methods Study group consisted of 110 patients with CKD in stages G3-G5 according to the KDIGO guidelines and was divided into four subgroups: treated conservatively (CT, 30 patients), on hemodialysis (HD, 30 patients), on peritoneal dialysis (PD, 30 patients) and renal transplant recipients (RT, 20 patients). In HD the blood was collected immediately before (HD D1) and after the dialysis (HD D2). In RT the blood was collected immediately before (RT D1) and 3–14 days after the transplantation (RT D2). The control group (Con) consisted of 50 healthy volunteers. Plasma concentrations of LPA and LPC were measured using enzyme-linked immunosorbent assays. Results In CT, PD and RT D2 plasma concentrations of LPA were significantly higher, compared to Con. In HD, LPA levels did not differ compared to Con and they were significantly lower compared to PD (HD D1 and HD D2), RT D2 (HD D1 and HD D2) and CT (HD D1). However, in most of patients concentrations of LPA were within the range of reference values established in healthy volunteers. Concentrations of LPC were significantly lower in almost all patients subgroups, compared to Con, except in PD. There were no significant correlations between plasma concentrations of LPA and LPC in any of patients subgroups. Conclusions Presence of CKD is associated with increased plasma LPA levels and the hemodialysis therapy reduces this influence. However, only in a small percentage of patients with CKD, LPA concentrations are out of the reference range, which makes LPA not useful as a diagnostic marker for CKD. Further studies are needed to confirm and explain observed relationships.http://link.springer.com/article/10.1186/s12944-019-1040-5Lysophosphatidic acidLPALysophosphatidylcholineLPCLysophospholipidsBioactive lipids |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Anna Michalczyk Barbara Dołęgowska Rafał Heryć Dariusz Chlubek Krzysztof Safranow |
spellingShingle |
Anna Michalczyk Barbara Dołęgowska Rafał Heryć Dariusz Chlubek Krzysztof Safranow Associations between plasma lysophospholipids concentrations, chronic kidney disease and the type of renal replacement therapy Lipids in Health and Disease Lysophosphatidic acid LPA Lysophosphatidylcholine LPC Lysophospholipids Bioactive lipids |
author_facet |
Anna Michalczyk Barbara Dołęgowska Rafał Heryć Dariusz Chlubek Krzysztof Safranow |
author_sort |
Anna Michalczyk |
title |
Associations between plasma lysophospholipids concentrations, chronic kidney disease and the type of renal replacement therapy |
title_short |
Associations between plasma lysophospholipids concentrations, chronic kidney disease and the type of renal replacement therapy |
title_full |
Associations between plasma lysophospholipids concentrations, chronic kidney disease and the type of renal replacement therapy |
title_fullStr |
Associations between plasma lysophospholipids concentrations, chronic kidney disease and the type of renal replacement therapy |
title_full_unstemmed |
Associations between plasma lysophospholipids concentrations, chronic kidney disease and the type of renal replacement therapy |
title_sort |
associations between plasma lysophospholipids concentrations, chronic kidney disease and the type of renal replacement therapy |
publisher |
BMC |
series |
Lipids in Health and Disease |
issn |
1476-511X |
publishDate |
2019-04-01 |
description |
Abstract Background Lysophosphatidic acid (LPA) and lysophosphatidylcholine (LPC) are bioactive lysophospholipids involved in the pathogenesis of renal diseases, especially the renal fibrosis. Plasma LPC concentrations in chronic kidney disease (CKD) patients are lower or similar to those observed in control groups, but less is known about the LPA concentrations. The main aim of the study was the analysis of associations of chronic kidney disease and renal replacement therapy with the plasma LPA concentrations. We have also analyzed the relationship between the plasma concentrations of LPA and LPC. Material and methods Study group consisted of 110 patients with CKD in stages G3-G5 according to the KDIGO guidelines and was divided into four subgroups: treated conservatively (CT, 30 patients), on hemodialysis (HD, 30 patients), on peritoneal dialysis (PD, 30 patients) and renal transplant recipients (RT, 20 patients). In HD the blood was collected immediately before (HD D1) and after the dialysis (HD D2). In RT the blood was collected immediately before (RT D1) and 3–14 days after the transplantation (RT D2). The control group (Con) consisted of 50 healthy volunteers. Plasma concentrations of LPA and LPC were measured using enzyme-linked immunosorbent assays. Results In CT, PD and RT D2 plasma concentrations of LPA were significantly higher, compared to Con. In HD, LPA levels did not differ compared to Con and they were significantly lower compared to PD (HD D1 and HD D2), RT D2 (HD D1 and HD D2) and CT (HD D1). However, in most of patients concentrations of LPA were within the range of reference values established in healthy volunteers. Concentrations of LPC were significantly lower in almost all patients subgroups, compared to Con, except in PD. There were no significant correlations between plasma concentrations of LPA and LPC in any of patients subgroups. Conclusions Presence of CKD is associated with increased plasma LPA levels and the hemodialysis therapy reduces this influence. However, only in a small percentage of patients with CKD, LPA concentrations are out of the reference range, which makes LPA not useful as a diagnostic marker for CKD. Further studies are needed to confirm and explain observed relationships. |
topic |
Lysophosphatidic acid LPA Lysophosphatidylcholine LPC Lysophospholipids Bioactive lipids |
url |
http://link.springer.com/article/10.1186/s12944-019-1040-5 |
work_keys_str_mv |
AT annamichalczyk associationsbetweenplasmalysophospholipidsconcentrationschronickidneydiseaseandthetypeofrenalreplacementtherapy AT barbaradołegowska associationsbetweenplasmalysophospholipidsconcentrationschronickidneydiseaseandthetypeofrenalreplacementtherapy AT rafałheryc associationsbetweenplasmalysophospholipidsconcentrationschronickidneydiseaseandthetypeofrenalreplacementtherapy AT dariuszchlubek associationsbetweenplasmalysophospholipidsconcentrationschronickidneydiseaseandthetypeofrenalreplacementtherapy AT krzysztofsafranow associationsbetweenplasmalysophospholipidsconcentrationschronickidneydiseaseandthetypeofrenalreplacementtherapy |
_version_ |
1725085615959048192 |